羚锐制药(600285) - 2020 Q1 - 季度财报

Financial Performance - Operating revenue decreased by 15.42% to CNY 491,104,302.97 year-on-year[12] - Net profit attributable to shareholders decreased by 24.23% to CNY 76,533,970.51 compared to the same period last year[12] - Basic earnings per share decreased by 21.97% to CNY 0.135 compared to the previous year[12] - The company reported a decrease in net profit after deducting non-recurring gains and losses by 17.03% to CNY 74,246,796.91[12] - The company reported a decrease in sales expenses to $249.54 million in Q1 2020 from $290.25 million in Q1 2019, a reduction of 14.0%[45] - Net profit for Q1 2020 was $76.22 million, a decline of 24.0% from $100.34 million in Q1 2019[48] - Total comprehensive income for Q1 2020 was $71.61 million, a decrease of 47.3% from $135.73 million in Q1 2019[48] Assets and Liabilities - Total assets increased by 6.08% to CNY 3,517,218,018.05 compared to the end of the previous year[12] - Total liabilities amounted to CNY 1,225,164,639.72, up from CNY 1,095,331,468.09, reflecting an increase of approximately 11.87%[35] - Current liabilities rose to CNY 1,145,779,760.40, compared to CNY 1,013,790,659.56, an increase of about 12.99%[32] - Total current assets increased to CNY 1,976,255,233.43, up from CNY 1,754,360,754.13 at the end of the previous year[29] - The total current liabilities included short-term borrowings of $135 million and accounts payable of approximately $71.66 million[70] Cash Flow - Net cash flow from operating activities decreased by 13.58% to CNY 139,446,429.04 year-on-year[12] - The company's cash flow from operating activities decreased by 13.58% to CNY 139,446,429.04 compared to the previous year[27] - The company incurred a net cash outflow from investing activities of approximately ¥170.89 million in Q1 2020, compared to a net outflow of ¥48.32 million in Q1 2019[56] - Cash inflow from financing activities in Q1 2020 was CNY 100,000,000.00, down 31.0% from CNY 145,000,000.00 in Q1 2019[60] Shareholder Information - The total number of shareholders at the end of the reporting period was 38,222[18] - The largest shareholder, Henan Lingrui Group Co., Ltd., holds 21.45% of the shares, with 121,817,898 shares pledged[18] - Shareholders' equity increased to CNY 2,292,053,378.33 from CNY 2,220,446,251.23, representing a growth of about 3.23%[35] Government Subsidies and Other Income - The company received government subsidies closely related to its normal business operations amounting to CNY 2,601,686.21[14] - Other income dropped by 77.22% to CNY 2,601,922.81, mainly due to reduced government subsidies received in the previous year[24] Investment and Financial Performance - Investment income showed a loss of CNY 219,589.51, a significant improvement from a loss of CNY 2,225,274.54 in the previous year[24] - The fair value changes in financial assets resulted in a loss of CNY 772,685.63, compared to a gain of CNY 3,468,636.42 in the previous year[24] - The company reported a retained earnings balance of approximately $1.001 billion, indicating strong profitability retention[65] Other Financial Metrics - The weighted average return on net assets decreased by 1.35 percentage points to 3.40%[12] - The company's tax and additional fees decreased by 36.85% to CNY 6,142,752.52 compared to the same period last year, primarily due to a decline in revenue[24] - Research and development expenses were $9.65 million in Q1 2020, slightly down from $9.99 million in Q1 2019[45]